Alcon's Clareon Panoptix Pro IOL enhances cataract surgery with advanced light utilization and low visual disturbance.

Alcon, the global leader in eye care, offers a broad portfolio of products to enhance sight and improve lives for patients in more than 140 countries.

LumiThera’s PBM is the only device that has demonstrated meaningful vision improvement compared to baseline for people living ...

Alcon has inked a deal to acquire LumiThera and its light-based therapy for dry age-related macular degeneration, which ...

HROW sets ambitious price targets in a new 3-year plan while showcasing strong drug growth and leveraging a proven model for ...

Alcon Announces FDA Approval of TRYPTYR (acoltremon ophthalmic solution) 0.003% for the Treatment of the Signs and Symptoms of Dry Eye Disease“Many of my patients continue to face frustrating ...

Alcon Inc.’s ALC UNITY Vitreoretinal Cataract System (“VCS”) has recently received approval from Health Canada. UNITY VCS is ...

Alcon AG plans to acquire Lumithera Inc., adding its photobiomodulation (PBM) device designed to treat early and intermediate ...

Alcon Laboratories has issued a recall for a specific lot of 'Systane Lubricant Eye Drops Ultra PF' due to potential fungal contamination.

Alcon Announces FDA Approval of TRYPTYR (acoltremon ophthalmic solution) 0.003% for the Treatment of the Signs and Symptoms of Dry Eye Disease ...